Current Allergy and Asthma Reports最新文献_第8页

The Impact of Artificial Intelligence on Allergy Diagnosis and Treatment. 人工智能对过敏症诊断和治疗的影响。

IF 5.4 2区医学

Current Allergy and Asthma Reports Pub Date : 2024-07-01 Epub Date: 2024-07-02 DOI: 10.1007/s11882-024-01152-y

Maham Khan, Sandipta Banerjee, Sakshi Muskawad, Rick Maity, Shubhayu Roy Chowdhury, Rida Ejaz, Ekins Kuuzie, Travis Satnarine

{"title":"The Impact of Artificial Intelligence on Allergy Diagnosis and Treatment.","authors":"Maham Khan, Sandipta Banerjee, Sakshi Muskawad, Rick Maity, Shubhayu Roy Chowdhury, Rida Ejaz, Ekins Kuuzie, Travis Satnarine","doi":"10.1007/s11882-024-01152-y","DOIUrl":"10.1007/s11882-024-01152-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>Artificial intelligence (AI), be it neuronal networks, machine learning or deep learning, has numerous beneficial effects on healthcare systems; however, its potential applications and diagnostic capabilities for immunologic diseases have yet to be explored. Understanding AI systems can help healthcare workers better assimilate artificial intelligence into their practice and unravel its potential in diagnostics, clinical research, and disease management.</p><p><strong>Recent findings: </strong>We reviewed recent advancements in AI systems and their integration in healthcare systems, along with their potential benefits in the diagnosis and management of diseases. We explored machine learning as employed in allergy diagnosis and its learning patterns from patient datasets, as well as the possible advantages of using AI in the field of research related to allergic reactions and even remote monitoring. Considering the ethical challenges and privacy concerns raised by clinicians and patients with regard to integrating AI in healthcare, we explored the new guidelines adapted by regulatory bodies. Despite these challenges, AI appears to have been successfully incorporated into various healthcare systems and is providing patient-centered solutions while simultaneously assisting healthcare workers. Artificial intelligence offers new hope in the field of immunologic disease diagnosis, monitoring, and management and thus has the potential to revolutionize healthcare systems.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"361-372"},"PeriodicalIF":5.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bioaerosol Exposures and Respiratory Diseases in Cannabis Workers. 大麻工人的生物气溶胶暴露和呼吸道疾病。

IF 5.4 2区医学

Current Allergy and Asthma Reports Pub Date : 2024-07-01 Epub Date: 2024-06-15 DOI: 10.1007/s11882-024-01157-7

Tess Eidem, Tara Nordgren, Mark Hernandez

{"title":"Bioaerosol Exposures and Respiratory Diseases in Cannabis Workers.","authors":"Tess Eidem, Tara Nordgren, Mark Hernandez","doi":"10.1007/s11882-024-01157-7","DOIUrl":"10.1007/s11882-024-01157-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review investigates occupational inhalation hazards associated with biologically derived airborne particles (bioaerosols) generated in indoor cannabis cultivation and manufacturing facilities.</p><p><strong>Recent findings: </strong>Indoor cannabis production is growing across the US as are recent reports of respiratory diseases among cannabis workers, including occupational asthma morbidity and mortality. More information is needed to understand how bioaerosol exposure in cannabis facilities impacts worker health and occupational disease risk. Preliminary studies demonstrate a significant fraction of airborne particles in cannabis facilities are comprised of fungal spores, bacteria, and plant material, which may also contain hazardous microbial metabolites and allergens. These bioaerosols may pose pathogenic, allergenic, toxigenic, and pro-inflammatory risks to workers. The absence of multi-level, holistic bioaerosol research in cannabis work environments necessitates further characterization of the potential respiratory hazards and effective risk prevention methods to safeguard occupational health as the cannabis industry continues to expand across the US and beyond.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"395-406"},"PeriodicalIF":5.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141328169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allergic Conjunctivitis Management: Update on Ophthalmic Solutions. 过敏性结膜炎管理：最新眼科解决方案。

IF 5.4 2区医学

Current Allergy and Asthma Reports Pub Date : 2024-07-01 Epub Date: 2024-06-13 DOI: 10.1007/s11882-024-01150-0

Andrea Leonardi, Luigi Quintieri, Ignacio Jáuregui Presa, Jesús Merayo LLoves, Jesús Montero, José Manuel Benítez-Del-Castillo, Francisco Javier Seoane Lestón, Eloína González-Mancebo, Riccardo Asero, Anna Groblewska, Piotr Kuna

{"title":"Allergic Conjunctivitis Management: Update on Ophthalmic Solutions.","authors":"Andrea Leonardi, Luigi Quintieri, Ignacio Jáuregui Presa, Jesús Merayo LLoves, Jesús Montero, José Manuel Benítez-Del-Castillo, Francisco Javier Seoane Lestón, Eloína González-Mancebo, Riccardo Asero, Anna Groblewska, Piotr Kuna","doi":"10.1007/s11882-024-01150-0","DOIUrl":"10.1007/s11882-024-01150-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>The aim of this review, is to present an updated revision of topical management of SAC and PAC, based on the available scientific evidence and focused on the impact of ophthalmic solution formulations on eye surface.</p><p><strong>Recent findings: </strong>Physicians treating ocular allergy should be aware of tear film and tear film disruption in SAC and PAC, and how eye drop composition and additives affect the physiology of the allergic eye. Seasonal and perennial allergic conjunctivitis (SAC and PAC) are the most frequent causes of ocular allergy (OA), and both conditions are underdiagnosed and undertreated. SAC and PAC are immunoglobulin E (IgE)-mediated hypersensitivity reactions. The additional tear film disruption caused by the release of inflammatory mediators increases and exacerbates the impact of signs and symptoms and may trigger damage of the ocular surface. Comorbidities are frequent, and dry eye disease in particular must be considered. Clinical guidelines for the management of SAC and PAC recommend topical therapy with antihistamines, mast cells stabilizers or dualaction agents as first-line treatment, but care should be taken, as many medications contain other compounds that may contribute to ocular surface damage.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"347-360"},"PeriodicalIF":5.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141312346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis of Allergic Dermatoses in Skin of Color. 有色人种过敏性皮肤病的诊断。

IF 5.4 2区医学

Current Allergy and Asthma Reports Pub Date : 2024-06-01 Epub Date: 2024-05-22 DOI: 10.1007/s11882-024-01148-8

Angelica Nazarian, Andrew F Alexis

引用次数: 0

The role of the environment in allergic skin disease. 环境在过敏性皮肤病中的作用。

IF 5.5 2区医学

Current Allergy and Asthma Reports Pub Date : 2024-06-01 Epub Date: 2024-05-11 DOI: 10.1007/s11882-024-01147-9

Khushnood Faraz, Mason Seely, Anne L Marano

引用次数: 0

Environmental Interventions for Preventing Atopic Diseases. 预防特应性疾病的环境干预措施。

IF 5.5 2区医学

Current Allergy and Asthma Reports Pub Date : 2024-05-01 Epub Date: 2024-03-16 DOI: 10.1007/s11882-024-01141-1

Scott Pfirrman, Ashley Devonshire, Andrew Winslow

{"title":"Environmental Interventions for Preventing Atopic Diseases.","authors":"Scott Pfirrman, Ashley Devonshire, Andrew Winslow","doi":"10.1007/s11882-024-01141-1","DOIUrl":"10.1007/s11882-024-01141-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>In this review, we detail the exposome (consisting of environmental factors such as diet, microbial colonization, allergens, pollutants, and stressors), mechanistic and clinical research supporting its influence on atopic disease, and potentiation from climate change. We highlight contemporary environmental interventions and available evidence substantiating their roles in atopic disease prevention, from observational cohorts to randomized controlled trials, when available.</p><p><strong>Recent findings: </strong>Early introduction to allergenic foods is an effective primary prevention strategy to reduce food allergy. Diverse dietary intake also appears to be a promising strategy for allergic disease prevention, but additional study is necessary. Air pollution and tobacco smoke are highly associated with allergic disease, among other medical comorbidities, paving the way for campaigns and legislation to reduce these exposures. There is no clear evidence that oral vitamin D supplementation, prebiotic or probiotic supplementation, daily emollient application, and antiviral prophylaxis are effective in preventing atopic disease, but these interventions require further study. While some environmental interventions have a well-defined role in the prevention of atopic disease, additional study of many remaining interventions is necessary to enhance our understanding of their role in disease prevention. Alignment of research findings from randomized controlled trials with public policy is essential to develop meaningful public health outcomes and prevent allergic disease on the population level.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"233-251"},"PeriodicalIF":5.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140141118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnancy and the Autoimmune Patient. 妊娠与自身免疫性疾病患者

IF 5.5 2区医学

Current Allergy and Asthma Reports Pub Date : 2024-05-01 Epub Date: 2024-04-02 DOI: 10.1007/s11882-024-01143-z

Brooke S Mills, Bonnie L Bermas

引用次数: 0

Minimally Invasive Approaches to Diagnose and Monitor Eosinophilic GI Diseases. 诊断和监测嗜酸性粒细胞消化道疾病的微创方法。

IF 5.5 2区医学

Current Allergy and Asthma Reports Pub Date : 2024-05-01 Epub Date: 2024-03-27 DOI: 10.1007/s11882-024-01142-0

Ellie J M Furuta, Glenn T Furuta, Robin Shandas

{"title":"Minimally Invasive Approaches to Diagnose and Monitor Eosinophilic GI Diseases.","authors":"Ellie J M Furuta, Glenn T Furuta, Robin Shandas","doi":"10.1007/s11882-024-01142-0","DOIUrl":"10.1007/s11882-024-01142-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review seeks to understand novel avenues for eosinophilic GI disease management. Biomarkers offer a unique and non-invasive approach to tracking EoE disease progression. While no biomarkers have definitively met the diagnostic criteria for eosinophilic GI diseases, some biomarkers have been shown to be associated with disease activity. Here, we examine the potential of recently studied biomarkers.</p><p><strong>Recent findings: </strong>Current research shows advancements in blood, luminal fluid, and breath testing. Particular areas of interest include mRNA analyses, protein fingerprinting, amplicon sequence variants (ASVs), T cells and IgE receptors, eosinophilic cationic proteins, cytokines, and nitric oxide exhalation. Preliminary results showed that mucosal biomarkers, directly captured from the esophagus, may reflect the best representation of biopsy-based results, in contrast to biomarkers obtained from indirect or peripheral (blood, breath) methods. However, this is based on limited clinical studies without sufficient numbers to evaluate true diagnostic accuracy. Large-scale randomized trials are needed to fully ascertain both the optimal sampling technique and the specific biomarkers that reflect diagnostic status of the disease.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"269-279"},"PeriodicalIF":5.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation and Modification of a Shared Decision-Making Tool for Peanut Allergy Management 评估和修改花生过敏管理的共同决策工具

IF 5.5 2区医学

Current Allergy and Asthma Reports Pub Date : 2024-04-19 DOI: 10.1007/s11882-024-01146-w

Aikaterini Anagnostou, Andrew Yaworsky, Monica Brova, Nazifa Ibrahim, Siddharth Kakked, Sasha Spite, Linette Duluc, Alan L. Shields, Tricia Lee, Stephanie Leonard, Kathy Przywara, Amelia Smith

{"title":"Evaluation and Modification of a Shared Decision-Making Tool for Peanut Allergy Management","authors":"Aikaterini Anagnostou, Andrew Yaworsky, Monica Brova, Nazifa Ibrahim, Siddharth Kakked, Sasha Spite, Linette Duluc, Alan L. Shields, Tricia Lee, Stephanie Leonard, Kathy Przywara, Amelia Smith","doi":"10.1007/s11882-024-01146-w","DOIUrl":"https://doi.org/10.1007/s11882-024-01146-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Based on shared decision-making (SDM) principles, a decision aid was previously developed to help patients, their caregivers, and physicians decide which peanut allergy management approach best suits them. This study refined the decision aid’s content to better reflect patients’ and caregivers’ lived experience.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Current standard of care for peanut allergy is avoidance, although peanut oral immunotherapy has been approved by the Food and Drug Administration for use in patients 4–17 years old.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>An advisory board of allergy therapy experts (<i>n</i> = 3) and patient advocates (<i>n</i> = 3) informed modifications to the decision aid. The revised tool underwent cognitive debriefing interviews (CDIs) among adolescents (12–17 years old) with peanut allergy and caregivers of patients 4–17 years old with peanut allergy to evaluate its relevance, understandability, and usefulness. The 20 CDI participants understood the information presented in the SDM tool and reported it was important and relevant. Some revisions were made based on participant feedback. Results support content validity of the Peanut Allergy Treatment SDM Tool.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"94 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140629527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis 中重度特应性皮炎新旧系统疗法的比较

IF 5.5 2区医学

Current Allergy and Asthma Reports Pub Date : 2024-04-18 DOI: 10.1007/s11882-024-01145-x

Hyun J. Yim, Tiffany Jean, Peck Y. Ong

{"title":"Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis","authors":"Hyun J. Yim, Tiffany Jean, Peck Y. Ong","doi":"10.1007/s11882-024-01145-x","DOIUrl":"https://doi.org/10.1007/s11882-024-01145-x","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Historically, systemic treatments for atopic dermatitis (AD) primarily consisted of immunosuppressive agents such as corticosteroids and Disease Modifying Antirheumatic Drugs (DMARDS), which provided symptomatic relief but often had long-term adverse effects. Newer treatments have shown significant efficacy with less side effects in clinical trials. This review discusses and compares conventional and newer systemic treatments for AD.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Newer medications for AD including dupilumab, tralokinumab, lebrikizumab, and oral JAK inhibitors have been shown to be safe and efficacious. High dose cyclosporine and dupilumab were more effective than methotrexate and azathioprine in improving clinical signs of AD. High-dose upadacitinib was shown in another meta-analysis to be most effective in the measured outcomes but had the highest frequency of adverse events.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Targeted biologic treatments are increasingly favored over traditional immunosuppressive treatments of AD. Treatment can be individualized based on potency, adverse side effects, mechanism of action, and administration preference. Ongoing research continues to expand treatment options for AD.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"19 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140616426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0